

Michael C. Sklar Francois Beloncle Christina M. Katsios Laurent <mark>Brochard</mark> Jan O. Friedrich

Extracorporeal carbon dioxide removal in patients with chronic obstructive pulmonary disease: a systematic review

Received: 29 April 2015 Accepted: 9 June 2015 Published online: 25 June 2015 © Springer-Verlag Berlin Heidelberg and ESICM 2015

Electronic supplementary material The online version of this article (doi:10.1007/s00134-015-3921-z) contains supplementary material, which is available to authorized users.

M. C. Sklar

Department of Anesthesiology, University of Toronto, Toronto, ON, Canada

M. C. Sklar · F. Beloncle · C. M. Katsios · L. Brochard () J. O. Friedrich Keenan Research Centre and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada e-mail: brochardl@smh.ca

F. Beloncle

Département de Réanimation Médicale et Médecine Hyperbare, Université d'Angers, CHU d'Angers, Angers, France

C. M. Katsios · L. Brochard · J. O. Friedrich Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada Abstract Introduction: Extracorporeal carbon dioxide removal (ECCO₂R) has been proposed for hypercapnic respiratory failure in chronic obstructive pulmonary disease (COPD) exacerbations, to avoid intubation or reduce length of invasive ventilation. Balance of risks, efficacy, and benefits of ECCO₂R in patients with COPD is unclear. Methods: We systematically searched MEDLINE and EMBASE to identify all publications reporting use of ECCO₂R in COPD. We looked at physiological and clinical efficacy. A favorable outcome was defined as prevention of intubation or successful extubation. Major and minor complications were compiled. *Results:* We identified 3123 citations. Ten studies (87 patients), primarily case series, met inclusion criteria. ECCO₂R prevented intubation in 65/70 (93 %) patients and assisted in the successful extubation of 9/17 (53 %) mechanically ventilated subjects. One casecontrol study matching to noninvasively ventilated controls reported lower intubation rates and hospital mortality with ECCO₂R that trended toward significance. Physiological

data comparing pre- to post-ECCO₂R changes suggest improvements for pH (0.07-0.15 higher), PaCO₂ (25 mmHg lower), and respiratory rate (7 breaths/min lower), but not PaO₂/FiO₂. Studies reported 11 major (eight bleeds requiring blood transfusion of 2 units, and three linerelated complications, including one death related to retroperitoneal bleeding) and 30 minor complications (13 bleeds, five related to anticoagulation, and nine clotting-related device malfunctions resulting in two emergent intubations). Conclu*sion:* The technique is still experimental and no randomized trial is available. Recognizing selection bias associated with case series, there still appears to be potential for benefit of ECCO₂R in patients with COPD exacerbations. However, it is associated with frequent and potentially severe complications. Higher-quality studies are required to better elucidate this risk-benefit balance.

Keywords Hypercapnia · Acute respiratory failure · Noninvasive ventilation

Introduction

Chronic obstructive pulmonary disease (COPD) is a major, worldwide health burden. It is currently the fourth

leading cause of death and will likely become the third leading cause of death worldwide by 2030 [1]. The chronic and progressive nature of COPD is commonly aggravated by exacerbations. Each exacerbation reflects disease progression, decreased quality of life, and an increased risk of death [2–4]. Classically, respiratory failure in COPD has been managed with noninvasive ventilation (NIV) [5], and <u>NIV</u> compared to <u>invasive</u> mechanical ventilation has been demonstrated to <u>reduce</u> mortality by almost half [6]. However, approximately <u>one-quarter to one-half</u> of these patients will <u>fail NIV</u> and require invasive mechanical ventilation (IMV) [7, 8]. The need for <u>IMV</u> heralds a <u>poor prognosis for COPD</u> exacerbations with <u>in-hospital survival</u> rates that range from <u>30 to 75 %</u> [9, 10]. The subset of patients who require IMV are also at increased risk of failed weaning and prolonged ventilation [10, 11].

Extracorporeal carbon dioxide removal (ECCO₂R) devices have been proposed as an adjunct in patients with both hypoxic and hypercapnic respiratory failure. ECCO₂R, as an experimental adjunct to mechanical ventilation in patients with hypercapnic acute respiratory failure secondary to COPD exacerbations, has been utilized to avoid intubation or reduce the length of invasive ventilation. The technology is not new; it was first used in patients by Gattinoni in the 1980s [12, 13], but has not achieved wide clinical use in part because of a high rate of complications. The general principle consists of an extracorporeal circuit similar to a continuous veno-venous hemofiltration circuit but with a membrane allowing the elimination of carbon dioxide (CO_2) from the blood. In comparison with veno-venous extracorporeal membrane oxygenation (ECMO) (allowing blood oxygenation in addition to CO_2 removal), much lower blood flows are required with ECCO₂R (300–1500 mL/min vs 3–5 L/min for ECMO), which allow the use of smaller vascular cannulas (ca. 14–18 Fr). However, as a result of the high risk of clotting, anticoagulation is needed. The risks and benefits of ECCO₂R in patients with COPD exacerbations are yet to be fully elucidated.

The majority of ECCO₂R literature describes its use in acute respiratory distress syndrome (ARDS) to allow very small tidal volume ("ultra-protective ventilation") [14–18]. In this situation, ECCO₂R counteracts hypercapnia induced by very low minute ventilation. Limited studies have examined its efficacy and safety in hypercapnic respiratory failure secondary to COPD exacerbations. Therefore, we undertook a systematic review to identify all the publications reporting the use of ECCO₂R devices in patients with exacerbations of COPD to determine the efficacy and safety of these devices in this disease.

Methods

Design

We conducted a systematic review with prespecified selection and outcome criteria. No review protocol was

separately published. We systematically searched multiple sources to identify all the publications reporting the use of ECCO₂R devices in patients with exacerbations of COPD. We searched the electronic databases Medline and Embase for articles and abstracts published before August 2014 using the following keywords: ECCOR, ECCO₂R, CO₂ removal, and extracorporeal. We also searched the bibliographies of included studies and review articles. We included articles published online at that time or published later in print. We searched the Clinical Trials Registry Database (http://clinicaltrials.gov) for registered unpublished and ongoing studies related to ECCO₂R and COPD. No language restrictions were applied. We included a study or a case report if at least 1 adult (over 18 years) patient with COPD was treated using ECCO₂R. Our primary outcomes of interest were the occurrence of a favorable outcome defined as the prevention of intubation in patients receiving NIV, or successful extubation when the device was implemented after intubation. Secondary clinical outcomes included ICU and hospital mortality and length of stay. Complications were classified as follows: major (death or life-threatening conditions in the absence of treatment, directly related to a device complication; transfusion of at least 2 units of packed red cells; or the need for open surgery) or minor (bleeding requiring less than 2 units of packed red cells; transient thrombocytopenia (at most 90×10^{9} /L) without clinical consequence; or non-lifethreatening event related to catheter insertion). Physiological outcomes included changes in the respiratory parameters, including pH, arterial partial pressure of carbon dioxide (PaCO₂) in mmHg, respiratory rate (RR) in breaths per minute; and changes in PaO₂/FiO₂ (the fraction of inspired oxygen) in mmHg as a measure of oxygenation.

Study selection

Two authors (MS and FB) independently reviewed the retrieved abstracts and assessed eligibility. Full-text review was conducted when either of the reviewers of the abstracts felt that the citations might meet inclusion criteria. Disagreement was resolved by consensus with a third author (LB).

Data extraction

Data from included studies were independently extracted by MS, FB, CK, and JF. We extracted the following data: study design, study and participant characteristics, study device, mode of extracorporeal access, device type, mode of ventilator support, study intervention, relevant outcome data, duration of ECCO₂R use, and complications. All included studies were assessed for bias using the Cochrane Collaboration risk of bias tool [19].

Data analysis

Because most of the retrieved studies were case reports and case series without control patients, the proportion of ECCO₂R patients with favorable clinical outcomes (prevention of intubation or successful extubation) and with complications were described but not pooled. Similarly the secondary clinical outcomes. ICU and hospital mortalities and lengths of stay, were also not pooled. Changes in physiological outcomes (pH, PaCO₂, RR, PaO₂/FiO₂) comparing pre-initiation values separately to values at 1, 6, and 24 h after initiation of ECCO₂R were pooled by calculating the differences in values for each physiological outcome for individual patients before and after $ECCO_2R$, when available, and then calculating the means and standard deviations of these differences. When only group means and standard deviations were available for pre- and post-ECCO₂R values, the difference was calculated and the standard deviation of the difference in means was calculated assuming a correlation (ρ) of 0.6. This was based on calculated ρ values ranging between 0.5 and 0.7 in the studies that provided individual patient pre- and post-ECCO₂R values. Sensitivity analyses using both a high degree of correlation ($\rho = 0.9$) and no correlation ($\rho = 0$) resulted in no significant changes for any of the analyses. Medians and interquartile ranges [20] or ranges [21] were converted to means and standard deviations using previously published methods, where necessary [20]. Trial results were pooled using the generic inverse variance weighting method in Review Manager (RevMan version 5.2; Cochrane Collaboration, Oxford, UK) with a two-sided significance level of 5 %. Individual trial and summary results are reported with 95 % confidence intervals (CIs). Random effects models which incorporate between-trial heterogeneity and give wider and more conservative CIs when heterogeneity is present were used for all analyses [22]. Statistical heterogeneity among trials was assessed using the I^2 statistic, defined as the percentage of total variability across studies attributable to heterogeneity rather than chance, and using published guidelines for low ($I^2 = 25-49$ %), moderate $(I^2 = 50-74 \%)$, and high $(I^2 > 75 \%)$ heterogeneity [23]. Z tests of interaction were used to calculate interaction p values comparing pooled changes from pre-ECCO₂R between later and earlier times after ECCO₂R initiation (i.e., comparing the changes from pre-ECCO₂R at 6 vs 1 h, and 24 vs 6 h).

Results

Search results

Our search strategy identified 3123 citations. Of these, 2085 were removed from the analysis for not meeting

screening eligibility. Thirty-eight studies were extracted for full-text analysis, of which ten studies met inclusion criteria and were subsequently analyzed in detail (Supplementary Fig. 1).

Pending and/or ongoing clinical studies

We identified five ongoing studies related to ECCO₂R and COPD [24-28] on clinicaltrials.gov. A planned randomized controlled trial by Barrett [24] (target N = 24) will assess the time to cessation of NIV with the use of ECCO₂R as an adjunct to NIV in acute exacerbations of COPD. Nava has two ongoing prospective cohort studies, one of which will attempt to facilitate weaning in mechanically ventilated hypercapnic respiratory failure patients with the use of carbon dioxide removal [25] (target N = 15), while the other will facilitate reduction in PaCO₂ in stable COPD patients with chronic hypercapnic respiratory failure not responding to chronic NIV [26] (target N = 15). The ongoing prospective cohort ECLAIR study will use ECCO₂R to prevent intubation in patients with acute hypercapnic respiratory failure failing NIV [27] (target N = 30). Finally, the PALP-COPD randomized controlled trial (target N = 120) aims to facilitate extubation of patients with COPD exacerbations with the aid of $ECCO_2R$ [28].

Characteristics of included studies

In total, ten studies reporting on 87 patients were included in this systematic review (Table 1). This included three single-patient case reports, two of which used ECCO₂R in patients on NIV to avoid intubation [29, 30] and one in a mechanically ventilated patient to facilitate extubation [31]; four case series reporting on five invasively ventilated patients [32] and five [33], two [34], and six [35] patients receiving NIV, respectively. It also included three larger studies. One was a 20-patient case series that included seven patients on NIV at high likelihood of requiring mechanical ventilation, and two patients on NIV and 11 patients already on IMV who failed previous weaning attempts [36]. The other two were case control studies that compared 25 prospective ECCO₂R-treated NIV patients with 21 matched NIV historical control patients [37]; and 21 retrospective ECCO₂R-treated NIV patients from four centers with 21 matched control patients treated in one of the four centers over the same time period who had failed NIV and required mechanical ventilation [38].

Table 2 describes the device characteristics and the anticoagulation targets, when described. All studies implemented a pump-driven veno-venous $ECCO_2R$ device except the study by Kluge [38] that used the pumpless arteriovenous Novalung iLA device. Blood flow

Table 1 Studies included in syster	natic review with design, outcome, an	nd complication data				
References	Design	Patients	Clinical outcomes			Adverse events
			Intubation/extubation	Mortality Lengt (days)	th of stay	
Case control studies Del Sorbo [37]	Prospective cases matched with historical controls using multivariate matching software (GenMatch)	n = 25 NIV + ECCO ₂ R vs n = 21 NIV	22/25 (88 %) vs 14/21 (67 %) Avoided intubation (HR for requiring intubation 0.27, 95 % CI 0.07–0.98, $p = 0.047$)	Hospital: ICU: 2/25 (8 %) 8 (IQ vs vs vs (12 (IG p = 0.035) ($p = 1Hospivs vs vs (p = 0.035) (p = 1 (p = 10 = 1$ ($p = 0.035$) ($p = 10 = 1$ ($p = 1$ ($p = 1$) 0 = 1 ($p = 1$)	R 7-10) QR 6-15) 0.19) ital: QR 21-28) QR 13-36) 0.80)	Major complications: 4 3 major bleeds (requiring ≥2 units pRBC transfusion; 1 resulted in endotracheal intubation due to hemodynamic instability from retroperitoneal bleeding) 1 venous perforation at insertion site Minor complications: 9 6 clots in circuit (leading to immediate endotracheal intubation in 2 patients) 2 pump malfunction
Kluge [38]	Retrospective, cases (4 sites) matched with contemporaneous controls (from only 1 of the sites) based on diagnosis, age \pm 10 years, SAPS II \pm 6 at ICU admission, and pH \pm 0.05 ^a before ECCO ₂ R or intubation	<i>n</i> = 21 NIV + ECCO ₂ R vs n = 21 failed NIV requiring invasive ventilation	NIV + ECCO ₂ R 19/21 avoided intubation	28 day: ICU: 5/21 (24 %) 15 (r. vs vs vs 4/21 (19 %) 30 (r. ddj p 6 month: Hospi 7/21 (33 %) 23 (r. vs vs vs vs vs vs vs vs ddj p = 0.00)	(4-137) (4-66) (4-66) (4-137) (4-137) (4-248) (4-248)	 1 membrane lung failure Major complications: 2 2 major bleeds (requiring 2 units pRBC transfusion) 2 units pRBC transfusion) 7 minor bleeds 7 minor bleeds 1 femoral artery pseudoaneurysm 1 HIT
Case series: both avoidance of int Burki [36]	bation and successful extubation Case series	n = 9 NIV +ECCOR plus n = 11 invasive ventilation + ECCO ₂ R (no control)	Group 1: 7/7 acute NIV + ECCO ₂ R Group 2: 2/2 difficult-to-wean NIV intubation Group 3: 3/11 invasive ventilation + extubated	 P = 0.09 avoided intubation + ECCO₂R avoided - ECCO₂R successfi 	L VIII	Major complications: 5 1 death related to retroperitoneal bleeding 1 pneumothorax 3 major bleed (requiring ≥2 units pRBC transfusion) Minor complications: 3 2 thrombocytopenia
Case series and case reports: avoid Bonin [29] Burki [33]	ance of intubation Case report Case series	n = 1 NIV + ECCO ₂ R No control n = 5 NIV + ECCO ₂ R No control	1/1 avoided intubation 5/5 avoided intubation			1 DV 1 1 minor complication 1 minor bleed 3 minor complications 1 minor bleed 1 thrombocytopenia 1 transient hypotension

continued
-
e
q
Ta

References	Design	Patients	Clinical outcomes			Adverse events
			Intubation/extubation	Mortality	Length of stay (days)	
Crotti [30] Mani [34]	Case report Case series	$n = 1 \text{ NIV}$ $n = 2 \text{ NIV} + \text{ECCO}_2 \text{R}$	1/1 avoided intubation 2/2 avoided intubation			Not evaluated Minor complications: 1
Spinelli [35] Case series and case reports:	Case series	n = 6 NIV + ECCO ₂ R	6/6 avoided intubation			t infombocytopenia Not evaluated
successful extubation Abrams [32]	Case series	n = 5 invasive ventilation + ECCO ₂ R	5/5 successfully extubated Before initiation of ECCO ₂ R, all	ICU: 0/5 (0 %)	ICU: 10.2 ± 2.5	4 minor complications: 2 minor bleeds
Cardenas [31]	Case report	No control $n = 1$ invasive	hve subjects failed NIV 1/1 successfully extubated	Hospital: 0/5 (0 %)	Hospital: 15.6 土 8.6	2 related to anticoagulation None reported
		ventilation + ECCO ₂ R (no control)				

 $Mean \pm SD$

adj adjusted, DVT deep vein thrombosis, ECCO₂R extracorporeal removal of carbon dioxide, HIT heparin-induced thrombocytopenia, ICU intensive care unit, IQR interquartile range, NIV noninvasive group (84 vs 65 mmHg, p = 0.001). Also a higher percentage of patients were ventilation, PaCO₂ partial arterial pressure of carbon dioxide, pRBC packed red blood cell, r. range, SAPS II Simplified Acute Physiology Score II ECCO2R-treated the ECCO₂R initiation was higher in intubation or awaiting lung transplant in the ECCO₂R-treated group (43 vs 0 %) ^a Despite close match in pH (within 0.01), PaCO₂ before

parameters varied significantly among the studies, ranging from several hundred milliliters per minute to several liters per minute. Vascular cannulas ranged from 13 to 23 Fr, though many used a 15.5-Fr catheter with the Hemolung device. Anticoagulation targets were measured either by the activated partial thromboplastin time test (aPTT) or the activated clotting time test (ACT). Intravenous unfractionated heparin was used for anticoagulation.

Inclusion and exclusion criteria for ECCO₂R

Inclusion and exclusion criteria for ECCO₂R were documented in four studies: Del Sorbo [37], Kluge [38], Burki [36], and Abrams [32] (Table 3). In general, the indications for ECCO₂R included hypercapnic respiratory failure with clinical and laboratory evidence of worsening acid–base and respiratory parameters. Contraindications were more heterogeneous but included bleeding diathesis, thrombocytopenia, and inability to cannulate a central vein or central nervous system pathology.

Risk of bias

Since none of the studies meeting inclusion criteria were randomized controlled trials, the risk of bias of all studies was high with the exception of the Del Sorbo [37] trial which we graded as moderate (Supplemental Table 1).

Effect of interventions

Primary outcome

Eight studies presented data on intubation prevention [29, 30, 33–38] (Table 1). Seventy patients were included in the analysis on intubation prevention with an overall success rate of 65/70 (92.8 %) (Supplemental Fig. 3). The two case reports [29, 30] and three small case series [33-35] all reported a perfect success rate of preventing intubation when patients were placed on ECCO₂R, as did the larger case series of Burki et al. [36]. In the study by Kluge et al. [38], 2/21 (10%) ECCO₂R-treated NIV patients required IMV, compared to 21/21 (100 %) of the control patients. Finally, in the case-control study by Del Sorbo et al. [37], only 3/25 patients (12 %, 95 % CI 3-31 %) in the NIV + ECCO₂R group required intubation [due to device clotting (n = 2) or hemodynamic instability from retroperitoneal bleeding (n = 1)] vs 7/21 (33 %, 95 % CI 15–57 %) in the matched NIV-only group (HR 0.27, 95 % CI 0.07–0.98, p = 0.047).

ECCO₂R was utilized in 17 patients receiving IMV across one case report [31], one case series (n = 5) [32], and 11 patients from the Burki study [36]. The rate of successful extubation in this cohort was 9/17 (52.9 %)

Table 2 Device characteris	tics and anticoagulation s	trategies			
References	Device	Cannula size (Fr)	Blood flow (mL/min)	Anticoagulation target	Duration of support (days)
Del Sorbo [37] $(n = 21)$	Hemodec V_V	14	255 ± 78	aPTT (1.88 \pm 0.66) \times normal	1.21 ± 0.20
Kluge [38] $(n = 21)$ Burki [36] $(n = 20)$	Novalung A–V Hemolung (ALung)	13–17 15.5	1100 (range 600–1800) 431 \pm 74 (range 117–587)	aPTT range 1.5–1.8 × normal aPTT 1.5–2.3 × normal	Median 9 (range $1-116$) 4.3 \pm 2.5 (range 0.01-8)
Bonin [29] $(n = 1)$	Hemolung (ALung) V_V	15.5	Range 422–520	aPTT $1.5-2.3 \times \text{normal}$	6
Burki [33] $(n = 5)$	Hemolung (ALung) V–V	15.5	467 ± 130	Not reported	Not reported
Crotti [30] $(n = 1)$	Maquet V-V	Not reported	2000	Not reported	9
Mani [34] $(n = 2)$	Hemolung (ALung) V–V	15.5	Range 350–550	ACT1.2–1.6 \times normal	Mean 3
Spinelli [35] $(n = 6)$	Device not reported V–V	Not reported	2900 ± 500	Not reported	Not reported
Abrams [32] $(n = 5)$	Maquet V_V	20–23	Range 1000–1700	aPTT 1.3–2 \times normal	8 ± 3.2
Cardenas [31] $(n = 1)$	Maquet V-V	18	800	ACT $1.5-1.7 \times normal$	4
All studies used unfractiona noted otherwise	ted intravenous heparin fo	r anticoagulation. Norr	nal aPTT taken as 30 s and norm	al ACT as 120 s. Data are presented	I as mean \pm SD except where

(Supplemental Fig. 2). The single patient in the case report and all five patients in the small case series were successfully extubated following the implementation of $ECCO_2R$, but Burki's study successfully extubated only 3/11 (27 %).

Secondary clinical outcomes

Secondary clinical outcomes include ICU and hospital mortality and length of stay. Three studies presented data on mortality. Del Sorbo et al. [37]. found significantly reduced hospital mortality in patients receiving ECCO₂R compared to controls (8 % in the ECCO₂R group vs 35 % in the NIV alone group, p = 0.035). The case series by Abrams et al. [32] demonstrated a 100 % survival rate both to ICU discharge and hospital discharge in their uncontrolled series of five patients. Finally, Kluge et al. [38], in their two retrospectively compared groups, showed no significant difference in mortality at 28 days (19 % with ECCO₂R vs 24 % without ECCO₂R) or 6 months (both groups 33 %).

These same three studies presented length of stay data. Del Sorbo et al. [37] found nonsignificant differences in either ICU [8 (7, 10) vs 12 (6, 15); p = 0.19] or hospital length of stay [24 (21, 28) vs 22 (13, 36); p = 0.80] in their study groups (data presented as median (interquartile range), ECCO₂R vs no ECCO₂R). Similarly, Kluge et al. [38] found no differences in either median ICU or hospital length of stay in their ECCO₂R vs invasive ventilation groups (15 vs 30 days and 23 vs 42 days, respectively). Abrams et al.'s [32] case series reported an average \pm standard deviation ICU length of stay of 10.2 ± 2.5 days and a hospital length of stay of 15.6 ± 8.6 days.

Respiratory parameters

Compared to baseline, initiation of ECCO₂R very quickly and significantly improved pH (Fig. 1a and Supplemental Fig. 4a), PaCO₂ (Fig. 1b, Supplemental Fig. 4b), and RR (Fig. 1c, Supplemental Fig. 4c), even after the first hour; pH increased by 0.07 (95 % CI 0.06–0.09, p < 0.001; three studies [34, 37, 38], 48 patients) after 1 h, 0.11 (95 % CI 0.10-0.11, p < 0.001; three studies [34, 36, 38],29 patients) after 6 h, and 0.15 (95 % CI 0.10-0.20, p < 0.001; four studies [32, 34, 36, 38], 33 patients) after 24 h. There was no between-study heterogeneity in the 1-h and 6-h comparisons ($I^2 = 0$ %), but a high degree of heterogeneity in the 24-h comparison ($I^2 = 93$ %). The greater increase between 1 and 6 h was statistically significant (interaction p = 0.0005) but the increase between 6 and 24 h did not achieve statistical significance (interaction p = 0.06). PaCO₂ decreased around 25 mmHg similarly between 1 and 6 h, and between 6 and 24 h

Table 3 Inclusion and exclusion criteria for $ECCO_2R$

References	Inclusion	Exclusion
Del Sorbo [37]	$\geq\!\!2$ h of NIV with pH < 7.30 and PaCO_2 > 20 % above baseline and RR > 30 with accessory muscle use or paradoxical breathing	MAP < 60 mmHg Platelets $<30 \times 10^9/L$ INR > 1.5 Bleeding diathesis, central nervous system pathology within previous 3 months, epidural catheter, gastrointestinal bleeding within the previous 6 weeks, varices, chronic jaundice/cirrhosis/ascites, trauma Body weight >120 kg
Kluge [38] Burki [36]	Worsening respiratory acidosis and oxygenation, increasing RR, and clinical signs suggestive of respiratory muscle fatigue and/or increased work of breathing despite NIV	None provided, but unable to cannulate 3 patients due to too severe peripheral vascular disease
	≥ 1 h of NIV with PaCO ₂ > 55 and pH $< 7.25,$ or pH < 7.30 and PaCO ₂ > 55 with $<\!\!5$ mmHg PaCO ₂ decrease from baseline following NIV application	Hemodynamic instability, sensitivity to heparin, recent major surgery, uncontrolled arrhythmia, thrombocytopenia (platelets $<100 \times 10^9$ /L), bleeding diathesis, coma
Abrams [32]	Exacerbation of COPD, respiratory failure with an ongoing requirement for NIV, and a preintubation arterial blood gas (ABG) with pH < 7.35 and PaCO2 > 55 mm Hg	NYHA class IV functional status or evidence of decompensated congestive heart failure, advanced malignancy, body mass index greater than 31.1 kg/m ² for men or greater than 32.2 kg/m ² for women, acquired immunodeficiency syndrome or other severely immunocompromised condition, PaO ₂ to FiO ₂ ratio consistently less than 250 mmHg, history of intracranial bleeding, known or suspected pregnancy, history of complications from extracorporeal support, inability to receive blood products, known hypersensitivity to heparin or history of heparin- induced thrombotic thrombocytopenia, inability to ambulate within 7 days before hospital admission anatomic abnormalities that would preclude catheter placement in the neck, severe bleeding diathesis, severe malnutrition or cachexia, and severely debilitated state



Fig. 1 Physiological parameters, data expressed as mean \pm SD. **a** pH Overall change in pH was 0.07–0.15 increase; p < 0.0001, *p < 0.001 at each time measurement vs pre-ECCO₂R; p = 0.005**b** Overall decrease in PaCO₂ was 24–26 mmHg vs pre-ECCO₂R, $p \le 0.0009$. **c** Overall change in respiratory rate was 6–8 breaths/ min lower vs pre-ECCO₂R, $p \le 0.008$. **d** No significant change in for interaction 1 vs 6 h, p = 0.06 for interaction 6 h vs 1 day. PaO₂/FiO₂ 1 h or 1 day vs pre-ECCO₂R

(interaction p > 0.05) with moderate to high heterogeneity in the 1-h and 24-h comparisons ($I^2 = 55$ and 77 %, respectively) (Fig. 1b). Few studies reported RR (only one study reported 6-h and 24-h data). Decreases of around 6–8 breaths per min were similar at all time points (interaction $p \ge 0.05$) with high between study heterogeneity at 1 h ($I^2 = 93$ %), the only comparison with data from more than one study. PaO₂/FiO₂ was reported only in single studies at 1 h [37] and 24 h [38], thereby precluding pooling, and was not significantly changed by ECCO₂R (Fig. 1d; Supplemental Fig. 4d).

Only one study compared physiological values in patients treated with ECCO₂R to matched controls. This matched case–control study reported statistically significant improvements at 1 h in pH by 0.06 (p = 0.0003), PaCO₂ by 17 mmHg (p = 0.01), and RR by 5 breaths/min (p = 0.0002), and a worsening in PaO₂/FiO₂ by 57 mmHg (p = 0.0006) [37].

Complications

All but two studies [30, 35] reported on ECCO₂R-related complications (these two case reports did not report any information on complications). We found a total of 11 major and 30 minor complications in the included studies (Table 1; Fig. 2). Of the major complications, 8/11 (72.7 %) (Table 1) were clinically significant bleeding episodes requiring at least 2 units of packed red cells (with one patient requiring endotracheal intubation due to hemodynamic instability from retroperitoneal bleeding). The three remaining major complications consisted of one venous perforation at the catheter insertion site, one pneumothorax, and one death related to a retroperitoneal bleed secondary to perforation of an iliac vein.

Of the 30 minor complications (Table 1) we found 13 minor bleeding episodes related either to device insertion or due to systemic anticoagulation. There were four episodes of transient thrombocytopenia and one occurrence of heparin-induced thrombocytopenia. There was one reported deep venous thrombosis, one femoral artery pseudoaneurysm, and one episode of transient systemic hypotension. Nine complications were related to device malfunction in the form of circuit clotting (n = 6), pump malfunction (n = 2), and membrane failure (n = 1), two of which resulted in emergent intubations.

Discussion

This exhaustive systematic review evaluated the efficacy and safety of the experimental use of $ECCO_2R$ in 87 patients with hypercapnic respiratory failure across ten



Fig. 2 Distribution of complications: a Major and b minor complications. *DVT* deep venous thrombosis

studies, primarily from cases series and case reports [29– 36], and two studies which matched patients treated with $ECCO_2R$ to historical controls [37, 38]. The overall level of evidence of the studies included is of relatively low quality, but this review still provides an estimate of $ECCO_2R$ -related physiological changes and complications. The majority of patients in this review were either successfully weaned from mechanical ventilation or <u>sustained on NIV</u>, avoiding intubation. These high success rates, however, must be interpreted very cautiously given the clear selection bias associated with case series data.

The data presented in the included studies were quite heterogeneous. Outside our primary outcome, only three studies presented data on ICU and hospital length of stay and mortality. The available physiological data, comparing primarily pre- to post-ECCO₂R changes in the same patients, suggest rapid and sustained improvements in ventilatory parameters including pH, PaCO₂, and respiratory rate, but not in oxygenation as measured using PaO₂/FiO₂. On the basis of limited data, pH continued to improve between 1 and 24 h post initiation, whereas PaCO₂ and respiratory rate did not show significant further improvements after 1 h. If this finding based on limited data is accurate, this suggests that the improvement in pH between 1 and 24 h may be attributable to improvements in metabolic rather than respiratory acidosis which could be due to factors such as improved circulation (reducing possible elevated lactate) or administration of diuretics or buffers (e.g., citrate loading from massive blood transfusions). Unfortunately, the included studies did not provide enough additional data to test these hypotheses. It should be noted that these changes in physiological outcomes over time did not account for other ventilatory changes made by clinicians in response to the early improvements observed with ECCO₂R initiation, as these were generally not provided in the study reports.

The technical characteristics of ECCO₂R have potential advantages over ECMO, but these foreseeable gains may give rise to significant harm. A recent editorial by Brochard [39] highlights this controversy. The major advantage of ECCO₂R compared to ECMO is the considerably lower blood flow required: several hundred milliliters per minute vs several liters per minute for ECMO. The lower flow allows for the use of vascular cannulas similar in size to those used in continuous venovenous hemofiltration (approximately <u>14–18 Fr.</u> depending on device, in ECCO₂R vs upwards of <u>20 Fr</u> in ECMO). However one risk of the low flow ECCO₂R system is the risk of membrane and circuit clotting related to low flow and thus the <u>need</u> for therapeutic anticoagulation.

Eight of the ten included studies reported on complications. The types and rates of complications again varied across the studies and there were substantially more observed complications in the larger clinical trials (32 out of 41 total recorded complications), with only nine recorded in the case report and smaller case series. Almost half of the patients in this systematic review experienced an ECCO₂R-related complication (41/87, 47.1 %). About half of the total complications (21/41, 51.2 %) were bleeding episodes related to anticoagulation; eight were severe hemorrhagic events while 13 were minor bleeds. Retroperitoneal bleeding following femoral cannulation led to one death [36], while another patient required intubation due to resulting hemodynamic instability [37]. Several studies in our review reported no hemorrhagic complications [30, 31, 34, 35], which highlights the small sample sizes and differing protocols in the current body of literature.

Despite full anticoagulation we found nine thrombotic complications related to device failure. As we have previously noted [39], <u>membrane clotting or device failure</u> during ECCO₂R can be a life-threatening event, which may lead to a <u>rapid rise in carbon dioxide</u> and overwhelming respiratory acidosis necessitating prompt intubation of patients and/or significant changes to their respiratory support. Only in the Del Sorbo study [37] was there mention of two patients requiring intubation in the setting of decompensation secondary to membrane clotting. It is evident by the propensity for both hemorrhagic and thrombotic events that the optimal anticoagulation scheme that minimizes both of the above is yet to be fully elucidated.

The risks related specifically to central line insertion, including pneumothorax, venous perforation, accidental arterial puncture, aneurysm, hematoma formation, and infection occurred rarely in this review and this limited body of literature is insufficient to ascertain if there is an increased risk of these with ECCO₂R-sized cannulas. They do not seem low, however, compared to usual complication rates of central venous access or hemodialysis access [40, 41].

In several ECCO₂R studies the intravascular devices and blood flow rates are comparable to those used for continuous renal replacement therapies (CRRT). One of the ongoing studies utilizes a modified continuous venovenous hemofiltration system to provide ECCO₂R [26]. This suggests that these techniques may demonstrate similar complication rates. Direct comparison of complication rates, however, is difficult because one must consider not only technical characteristics of the system but the underlying pathobiology of the patient. The types and rates of complications among CRRT studies vary but a recent review sheds some light [42]. This group's experience with 1809 patients found a total complication rate of 46 %. The authors found a bleeding rate of 2.3 %. thrombosis rate of 2.5 %, and 15 episodes (0.8 %) of pneumothorax. Accidental arterial puncture occurred 5.7 % of the time and there was an infection rate of 17.2 %. There was no mention of dialysis membrane or circuit failures. These authors do not comment on blood flows, cannula sizes, or anticoagulation doses. Although a similar overall complication rate was seen in this large review of **CRRT** when compared to our review of $ECCO_2R$, the distribution of complications is different and the relative contribution of circuit/system complications remains unknown.

Other sources of heterogeneity include the types of $ECCO_2R$ devices, the anticoagulation schemes, sizes of the vascular cannulas, and one study [38] that used an arterio-venous pumpless system. How these factors affect the rates of hemorrhage or thrombosis and other complication risks is not known, strengthening the need for higher-quality studies.

Limitations

Although we used rigorous systematic review and metaanalytic methods including a reproducible and comprehensive literature search strategy, clearly defined inclusion criteria, and duplicate citation review, data abstraction, and quality assessment of individual studies, a protocol for our systematic protocol was not pre-published. In addition, we identified only low-level evidence, primarily case series data. These types of reports are at high risk of selection bias since unsuccessful case reports or series are generally not published. As a result of a lack of control groups for clinical outcomes, we were limited to pooling before-after physiological outcomes, recognizing that surrogate outcomes typically overestimate benefits in clinical outcomes [43]. In particular, the reported rates of intubation prevention and earlier extubation are likely optimistic estimates. Despite these significant limitations, this review describes and highlights the paucity of data in this field and provides practitioners with a description of how this technique has been implemented, summarizing the complications that have occurred and the changes in physiological outcomes that may be expected.

Conclusion

ECCO₂R is a fascinating technology that holds theoretical promise for the treatment of hypercapnic respiratory failure in the setting of COPD exacerbations. The current body of literature demonstrates that there is a paucity of highquality data. It suggests, however, that this experimental technology may be highly efficient from a physiological standpoint but is also not without risk; in addition to the risk associated with central line insertion, there is a delicate balance between hemorrhage and thrombosis. This analysis strongly supports the need for further research with physiological and safety studies, including randomized controlled trials to more clearly elucidate the risk–benefit balance of ECCO₂R in COPD exacerbations.

Conflicts of interest No author identifies a conflict of interest.

References

- Decramer M, Janssens W, Miravitlles M (2012) Chronic obstructive pulmonary disease. Lancet 379:1341–1351
- Soler-Cataluña JJ, Martínez-García MÁ, Sánchez PR et al (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931
- Connors AF, Dawson NV, Thomas C et al (1996) Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154:959–967
- Hoogendoorn M, Hoogenveen RT, Rutten-van Mölken MP et al (2011) Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 37:508–515
- Chandra D, Stamm JA, Taylor B et al (2012) Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998–2008. Am J Respir Crit Care Med 185:152–159
- Brochard L, Mancebo J, Wysocki M et al (1995) Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 333:817–822
- Quinnell TG, Pilsworth S, Shneerson JM, Smith IE (2006) Prolonged invasive ventilation following acute ventilatory failure in COPD: weaning results, survival, and the role of noninvasive ventilation. Chest 129:133–139

- Hoo GW, Hakimian N, Santiago SM (2000) Hypercapnic respiratory failure in COPD patients: response to therapy. Chest 117:169–177
- Chu CM, Chan VL, Lin AWN et al (2004) Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax 59:1020–1025
- Menzies R, Gibbons W, Goldberg P (1989) Determinants of weaning and survival among patients with COPD who require mechanical ventilation for acute respiratory failure. Chest 95:398–405
- Schönhofer B, Euteneuer S, Nava S et al (2002) Survival of mechanically ventilated patients admitted to a specialised weaning centre. Intensive Care Med 28:908–916
- Gattinoni L, Agostoni A, Pesenti A (1980) Treatment of acute respiratory failure with low-frequency positivepressure ventilation and extracorporeal removal of CO2. Lancet 2:292–294
- Gattinoni L, Pesenti A, Mascheroni D et al (1986) Low-frequency positivepressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure. JAMA 256:881–886
- Terragni PP, Del Sorbo L, Mascia L et al (2009) Tidal volume lower than 6 mL/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology 111:826–835

- 15. Bein T, Weber-Carstens S, Goldmann A et al (2013) Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus conventional protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med 39:847–856
- 16. Bein T, Weber F, Philipp A et al (2006) A new pumpless extracorporeal interventional lung assist in critical hypoxemia/hypercapnia. Crit Care Med 34:1372–1377
- Nierhaus A, Frings D, Braune S et al (2011) Interventional lung assist enables lung protective mechanical ventilation in acute respiratory distress syndrome. Minerva Anestesiol 77:797–801
- 18. Fitzgerald M, Millar J, Blackwood B et al (2014) Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review. Crit Care 18:222
- Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343:d5928
- 20. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. Wiley, USA
- 21. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13
- DerŜimonian R, Laird N (1986) Metaanalysis in clinical trials. Control Clin Trials 7:177–188

- 23. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
- 24. Barrett N, Camporota L, Hart N (2014) ECCO2R as an adjunct to NIV in AECOPD. http://ClinicalTrials.gov. NCT02086084
- Nava S (2014) Weaning form mechanical ventilation using extracorporeal CO2 removal (WeanPRO). http://ClinicalTrials.gov. NCT02259335
- Nava S (2014) Effect of extracorporeal CO2 removal in stable hypercapnic COPD patients. http://Clinicaltrials.gov. NCT02260583
- 27. Kluge S (2013) Extracorporeal lung assist to avoid intubation in patients failing noninvasive ventilation for acute hypercapnic respiratory Failure (ECLAIR). http://Clinicaltrials.gov. NCT01784367
- Ranieri VM (2014) The PALPTM-COPD trial (Low-flow CO2-removal (ECCO2-R) in exacerbated COPD) (PALP-COPD). http://Clinicaltrials.gov . NCT02107222
- 29. Bonin F, Sommerwerck U, Lund LW, Teschler H (2013) Avoidance of intubation during acute exacerbation of chronic obstructive pulmonary disease for a lung transplant candidate using extracorporeal carbon dioxide removal with the Hemolung. J Thorac Cardiovasc Surg 145:e43–e44

- Crotti S, Lissoni A, Tubiolo D et al (2012) Artificial lung as an alternative to mechanical ventilation in COPD exacerbation. Eur Respir J 39:212–215
- Cardenas VJ Jr, Lynch JE, Ates R et al (2009) Venovenous carbon dioxide removal in chronic obstructive pulmonary disease experience in one patient. ASAIO J 55:420–422
- 32. Abrams DC, Brenner K, Burkart KM et al (2013) Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc 10:307–314
- 33. Burki N, Mani R, Herth F, Schmidt W, Teschler H, Bonin F (2011) A novel extracorporeal CO₂ removal system: application of the hemolung in patients with hypercapnic respiratory failure. Am J Respir Crit Care Med 183:A1697
- Mani RK, Schmidt W, Lund LW, Herth FJF (2013) Respiratory dialysis for avoidance of intubation in acute exacerbation of COPD. ASAIO J 59:675–678
- 35. Spinelli E, Crotti S, Zacchetti L et al (2013) Effect of extracorporeal CO2 removal on respiratory rate in spontaneously breathing patients with chronic obstructive pulmonary disease exacerbation. Crit Care 17:S48
- 36. Burki NK, Mani RK, Herth FJF et al (2013) A novel extracorporeal CO(2) removal system: results of a pilot study of hypercapnic respiratory failure in patients with COPD. Chest 143:678–686

- 37. Del Sorbo L, Pisani L, Filippini C et al (2014) Extracorporeal CO2 Removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med 43:120–127
- 38. Kluge S, Braune SA, Engel M et al (2012) Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med 38:1632–1639
- 39. Beloncle F, Brochard L (2015) Extracorporeal CO2 removal for chronic obstructive pulmonary disease: too risky or ready for a trial? Crit Care Med 43:245–246
- Roux D, Reignier J, Thiery G et al (2014) Acquiring procedural skills in ICUs: a prospective multicenter study. Crit Care Med 42:886–895
- Ruesch S, Walder B, Tramèr MR (2002) Complications of central venous catheters: internal jugular versus subclavian access–a systematic review. Crit Care Med 30:454–460
- Bambauer R, Latza R (2004) Complications in large-bore catheters for extracorporeal detoxification methods. Artif Organs 28:629–633
- 43. Ciani O, Buyse M, Garside R et al (2013) Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: metaepidemiological study. BMJ 346:f457